Why did PPGN.SW stock jump in the pre-market session?

PPGN.SW stock rose after PolyPeptide reported preliminary 2025 revenue of about EUR389.00 million and an EBITDA margin of 11.0%–12.0%, boosting investor demand. Elevated volume (198,086) and positive technical momentum amplified the move.

What is Meyka AI's view and forecast for PPGN.SW stock?

Meyka AI rates PPGN.SW **65.60/100** (Grade B, HOLD). Meyka AI's forecast model projects **CHF31.67** yearly, implying about **0.86%** upside versus the current price of **CHF31.40**. Forecasts are projections, not guarantees.

What valuation and risks should investors watch for PPGN.SW stock?

Key metrics: PE **-32.37**, P/S **3.02**, P/B **3.38**, and EPS **-0.97**. Watch inventory days **175.83**, capex levels near EUR100.00 million, and upcoming earnings on 12 Mar 2026 as primary risks to the thesis.

Which catalysts could move PPGN.SW stock next?

Catalysts include the audited 2025 results, order-book updates for metabolic therapies, capex conversion to higher-margin output, and any analyst revisions following the 12 Mar 2026 earnings announcement.

CH Stocks

PPGN.SW up 6.98% to CHF31.40 pre-market 22 Jan 2026: analyst view ahead

ByHuzaifa Zahoor January 22, 2026January 22, 2026

PPGN.SW stock is trading higher in pre-market on 22 Jan 2026 after a jump to CHF31.40, up 6.98% from yesterday’s close. The move follows stronger-than-expected preliminary 2025 results showing revenue growth and margin improvement, lifting investor interest on the SIX Swiss Exchange. We examine what drove the gain, how the healthcare specialty peptide maker’s financials and technicals support the move, and what analysts and Meyka AI see next for trading and price targets.